StockData

Ascendis Pharma A/S vs Ionis Pharmaceuticals

ASND and IONS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ASND and IONS compare

Ascendis Pharma A/S grew revenue faster over the last twelve months (113% versus −7.4% for Ionis Pharmaceuticals).

Ascendis Pharma A/S keeps more of each dollar of sales as profit, with a net margin of 70.8% compared with −64.7% at Ionis Pharmaceuticals.

Ascendis Pharma A/S scores higher on the StockData Score (7 against 4 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricASNDIONS
Size and price
Market cap–$4.7B
Share price$271.73$28.01
Change, 1 year31.6%−59.9%
Change, 5 years88.9%−3.6%
Beta (5Y)0.500.55
Employees8791,402
StockData Score
Total score7 (better)4
Valuation score01 (better)
Growth score3 (better)2
Performance score2 (better)0
Health score2 (better)1
Dividend score00
Valuation
P/S–5.3×
P/B–10.6×
FCF yield–−12.0%
Fair value–$28.16
Margin of safety–0.55%
Growth
Revenue growth (TTM)113% (better)−7.4%
Revenue growth, 5Y average153% (better)5.3%
Profitability
Gross margin91.3%98.2% (better)
Operating margin25.4% (better)−68.0%
Net margin70.8% (better)−64.7%
FCF margin–−64.2%
Return on equity–−105%
Financial health
Net debt / EBITDA−1.61–
Interest coverage1.3× (better)−31.6×
Current ratio2.997.89 (better)
Altman Z-score–0.27
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions108%108%
Held by insiders0.83%0.81%
Insider net buying, 12 months−$4.7M (better)−$114M
Superinvestors holding–1
Short interest, % of float–12.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.